Search results for "CHRONIC HEPATITIS"

showing 10 items of 159 documents

The Italian ENTAS cohort study: Entecavir effectiveness in naïve and treatment experienced patients with chronic hepatitis B

2015

medicine.medical_specialtyHepatologyChronic hepatitisbusiness.industryInternal medicineGastroenterologyMedicineEntecavirbusinessTreatment experiencedmedicine.drugCohort studyDigestive and Liver Disease
researchProduct

Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B

2014

medicine.medical_specialtyHepatologyChronic hepatitisbusiness.industryInternal medicineGastroenterologymedicineEntecavirInterim analysisbusinessmedicine.drugCohort studyDigestive and Liver Disease
researchProduct

Error factors for transient elastography in chronic hepatitis C

2008

medicine.medical_specialtyHepatologyChronic hepatitisbusiness.industryInternal medicineGastroenterologymedicineTransient elastographybusinessGastroenterologyDigestive and Liver Disease
researchProduct

PNPLA3 rs738409 C>G SNP is associated with histological features of NASH in genotype 1 chronic hepatitis C patients

2014

medicine.medical_specialtyHepatologyChronic hepatitisbusiness.industryInternal medicineGenotypeGastroenterologymedicineSNPbusinessGastroenterologyDigestive and Liver Disease
researchProduct

Retrospective, observational, multicentre study on the Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combi…

2009

medicine.medical_specialtyHepatologyCombination therapybusiness.industryRibavirinGastroenterologyItalian populationGastroenterologySurgerychemistry.chemical_compoundChronic hepatitischemistryInternal medicinemedicineObservational studybusinessNadir (topography)Digestive and Liver Disease
researchProduct

Corrigendum to: “FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa…

2013

medicine.medical_specialtyHepatologyFibroTestbusiness.industryRibavirinIndependent predictorGastroenterologyPegylated interferon alfa-2bchemistry.chemical_compoundChronic hepatitischemistryVirologic responseInternal medicinemedicinebusinessJournal of Hepatology
researchProduct

Interferon-α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response

1994

To identify predictors of short-term and sustained ALT normalization after interferon treatment in adult patients with chronic hepatitis C, we performed a metanalysis of individual patients'data, with construction and cross-validation of a prediction rule, in 361 patients from two randomized trials. In one trial, 116 subjects with transfusion-related chronic hepatitis C were treated with lymphoblastoid interferon (5 MU/m 2 three times a week for 2 mo, then 3 MU/m 2 three times a week for 4 or 10 mo)

medicine.medical_specialtyHepatologybusiness.industryAlpha interferonGastroenterologylaw.inventionRandomized controlled trialChronic hepatitislawInterferonInternal medicineInterferon αImmunologymedicineViral diseaseLymphoblastoid InterferonbusinessInterferon alfamedicine.drugHepatology
researchProduct

Hepatitis C virus (HCV) infection in elderly patients: A multicenter Italian cross-sectional study

2009

medicine.medical_specialtyHepatologybusiness.industryCross-sectional studyHepatitis C virusGastroenterologyHEPATITIS C VIRUS INFECTIONCHRONIC HEPATITISmedicine.disease_causeHEPATITIS C VIRUS INFECTION; ELDERLY PATIENTS; CHRONIC HEPATITISInternal medicineELDERLY PATIENTSMedicinebusiness
researchProduct

Real life data on elbasvir/grazoprevir efficacy, safety and drug-drug interaction profile in patients with chronic hepatitis C viral infection: a pro…

2019

Introduction: In a previous study, based on PITER cohort data, it was reported that of patients, undergoing direct acting antiviral (DAA) therapy, 30%-44%, are at risk of potential drug-drug interactions (DDI). Aim: We aimed to evaluate the prospective profile of elbasvir/grazoprevir (EBR/GZR) efficacy and safety combined with real life comedication profile. Method: Data from 312 patients (mean age 63 ± 10 years; 44% male, 90% of genotype 1.85% fibrosis stage ≤ F3, 15% with child A cirrhosis), enrolled in PITER by 15 clinical centers and treated with EBR/GZR, with at least three months of follow up after the end of treatment, were evaluated. Comedication profiles (no changes, drugs interrup…

medicine.medical_specialtyHepatologybusiness.industryDrug-drug interactionGastroenterologyelbasvir grazoprevir efficacy drug-drug interaction Hepatitic HCV Piter cohortReal life dataViral infectionProspective analysisChronic hepatitisInternal medicineCohortmedicineElbasvir GrazoprevirIn patientbusinessDigestive and Liver Disease
researchProduct

Treatment of chronic hepatitis C

1991

alpha-Interferon given subcutaneously at doses between 1-3 million units leads to responses in about 50% of patients suffering from chronic hepatitis C. A 24-week treatment is frequently (approx. 50%) followed by relapses reducing the percentage of lasting responders to approx. 20%. The patients who relapse are sensitive to retreatment with interferon-alpha. A better understanding of HCV replication and of the interferon action in this viral disease might help to further improve treatment schedules. Side effects of interferon were frequently mild and readily reversible after cessation of treatment. At present interferon treatment should not be recommended in asymptomatic patients or individ…

medicine.medical_specialtyHepatologybusiness.industryTreatment outcomeInterferon-alphaHepacivirusVirus ReplicationProgressive liver diseaseHepatitis CAsymptomaticGastroenterologyTreatment OutcomeViral replicationChronic hepatitisInterferonInternal medicineChronic DiseaseImmunologyHumansMedicineViral diseaseMillion Unitsmedicine.symptombusinessmedicine.drugJournal of Hepatology
researchProduct